EQL Pharma AB (OSTO:EQL) EBIT: kr48.7 Mil (TTM As of Mar. 2026)

What is EQL Pharma AB EBIT?

EQL Pharma AB OSTO:EQL -2.32% 42 EBIT is kr48.7 Mil as of Mar. 2026. GuruFocus rates OSTO:EQL with a GF Score™ of 42/100. The stock has 4 warning signs investors should review.

EQL Pharma AB's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was kr5.1 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was kr48.7 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. EQL Pharma AB's annualized ROC % for the quarter that ended in Mar. 2026 was 2.94%. EQL Pharma AB's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 8.76%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. EQL Pharma AB's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 4.50%.

EQL Pharma AB (OSTO:EQL) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

EQL Pharma AB's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

	ROC % (Q: Mar. 2026 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Dec. 2025 )	+	Invested Capital (Q: Mar. 2026 ))	/ count )
=	20.456 * ( 1 - 0% )	/	( (695.537	+	693.874)	/ 2 )
=	20.456	/	694.7055
=	2.94 %

where

	Invested Capital		(Q: Dec. 2025 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	813.537	-	45.331	-	( 72.669	-	max(0, 174.366	-	376.727	+	72.669	))
=	695.537

	Invested Capital		(Q: Mar. 2026 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	850.887	-	70.256	-	( 86.757	-	max(0, 210.231	-	403.871	+	86.757	))
=	693.874

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

EQL Pharma AB's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Mar. 2026 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Dec. 2025		Q: Mar. 2026
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	20.464	/	( ( (5.417 + max(232.697, 0))	+	(5.903 + max(223.021, 0)) )	/	2 )
=	20.464	/	( ( 238.114	+	228.924 )	/	2 )
=	20.464	/	233.519
=	8.76 %

where Working Capital is:

	Working Capital		(Q: Dec. 2025 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(81.366	+	196.662	+	0)	-	(45.331	+	0	+	2.8421709430404E-14)
=	232.697

	Working Capital		(Q: Mar. 2026 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(92.744	+	200.533	+	0)	-	(70.256	+	0	+	0)
=	223.021

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

EQL Pharma AB's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Mar. 2026 )
	=	48.692	/	1082.001
	=	4.50 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

EQL Pharma AB EBIT Related Terms

EQL Pharma AB EBIT Historical Data

* Premium members only.

The historical data trend for EQL Pharma AB's EBIT can be seen below:

EQL Pharma AB EBIT Chart

EQL Pharma AB Annual Data

Trend

Dec16

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Mar25

Mar26

EBIT

Get a 7-Day Free Trial

38.84

41.34

34.34

67.38

48.69

EQL Pharma AB Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
EBIT	Get a 7-Day Free Trial															22.98	20.46	3.59	19.53	5.12

OSTO:EQL vs ZTS, UTHR: EBIT Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, EQL Pharma AB's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

EQL Pharma AB EV-to-EBIT vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, EQL Pharma AB's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where EQL Pharma AB's EV-to-EBIT falls into.

Save Embed

42GF Score

EQL Pharma AB OSTO:EQL

EBIT is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

EQL Pharma AB EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr48.7 Mil.

Frequently Asked Questions Learn more about EBIT →

What does a EBIT of kr48.7 Mil mean?

EQL Pharma AB (OSTO:EQL) has a EBIT of kr48.7 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on EQL Pharma AB.

Is EQL Pharma AB's EBIT too high?

EQL Pharma AB's current EBIT is kr48.7 Mil. Overall, EQL Pharma AB has a GF Score™ of 42/100, reflecting its overall financial health beyond just this single metric.

How does EQL Pharma AB's EBIT compare to ZTS and UTHR?

EQL Pharma AB's EBIT of kr48.7 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good EBIT for a Drug Manufacturers company?

A good EBIT depends on the Drug Manufacturers industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high EBIT mean?

A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on EQL Pharma AB. EQL Pharma AB's current EBIT is kr48.7 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is EQL Pharma AB stock overvalued right now?

EQL Pharma AB (OSTO:EQL) has a current EBIT of kr48.7 Mil. The current EBIT is kr48.7 Mil. EQL Pharma AB's overall GF Score™ is 42/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is EBIT calculated?

EBIT is calculated from a company's financial statements. For EQL Pharma AB (OSTO:EQL), the current EBIT is kr48.7 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

EQL Pharma AB Business Description

Industry Healthcare Drug Manufacturers

Comparable Companies OSTO:DICOT OSTO:NANEXA OSTO:ENZY OSTO:ORX OSTO:CINPHA OSTO:MOB OSTO:KLAR XSAT:ACUC OSTO:VIVE OSTO:NEWBRY XTER:MRK XSWX:GALD TSE:4502 SHSE:600276 NSE:SUNPHARMA LSE:HLN XTAE:TEVA XSWX:SDZ ZTS UTHR

Other Exchanges 7JK:Germany

Address Stortorget 1, 3rd Floor, Lund, SWE, 222 23

Website http://www.eqlpharma.com

EQL Pharma AB is a pharmaceutical company focused on efficiently and thoughtfully developing and marketing generic drugs. The company operates in one segment, which is medicine. Its niche generics are divided into four parts based on four sales and marketing models: Retail, Hospital, Branded, and Tests. EQL Pharma specializes in identifying, developing, and selling generics, i.e., medicines that are medically equivalent to originator medicines. The company operates in Sweden, Denmark, Norway, Finland, the rest of Europe, and outside Europe, generating the majority of its revenue from Sweden.

42GF Score

Get the complete analysis for OSTO:EQL

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr23.15

Price

View OSTO:EQL Analysis

See EBIT data for all stocks →